Literature DB >> 20536788

The role of natural killer T cells in costimulation blockade-based mixed chimerism.

Patrick-Nikolaus Nierlich1, Christoph Klaus, Sinda Bigenzahn, Nina Pilat, Zvonimir Koporc, Ines Pree, Ulrike Baranyi, Masaru Taniguchi, Ferdinand Muehlbacher, Thomas Wekerle.   

Abstract

Distinct lymphocyte populations have been identified that either promote or impede the establishment of chimerism and tolerance through allogeneic bone marrow transplantation (BMT). Natural killer T (NKT) cells have pleiotropic regulatory properties capable of either augmenting or downmodulating various immune responses. We investigated in this study whether NKT cells affect outcome in mixed chimerism models employing fully mismatched nonmyeloablative BMT with costimulation blockade (CB). The absence of NKT cells had no detectable effect on chimerism or skin graft tolerance after conditioning with 3Gy total body irradiation (TBI), and a limited positive effect with 1Gy TBI. Stimulation of NKT cells with alpha-galactosylceramide (alpha-gal) at the time of BMT prevented chimerism and tolerance. Activation of recipient (as opposed to donor) NKT cells was necessary and sufficient for the alpha-gal effect. The detrimental effect of NKT activation was also observed in the absence of T cells after conditioning with in vivo T-cell depletion (TCD). NKT cells triggered rejection of BM via NK cells as chimerism and tolerance were not abrogated when NKT cells were stimulated in the absence of both NK cells and T cells. Thus, activation of NKT cells at the time of BMT overcomes the effects of CB, inhibiting the establishment of chimerism and tolerance.
© 2010 The Authors. Journal compilation © 2010 European Society for Organ Transplantation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536788      PMCID: PMC2992941          DOI: 10.1111/j.1432-2277.2010.01120.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  54 in total

1.  NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.

Authors:  M J Smyth; N Y Crowe; D I Godfrey
Journal:  Int Immunol       Date:  2001-04       Impact factor: 4.823

2.  CD4(+) Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice.

Authors:  Y Ikehara; Y Yasunami; S Kodama; T Maki; M Nakano; T Nakayama; M Taniguchi; S Ikeda
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

3.  Requirement for natural killer T (NKT) cells in the induction of allograft tolerance.

Authors:  K I Seino; K Fukao; K Muramoto; K Yanagisawa; Y Takada; S Kakuta; Y Iwakura; L Van Kaer; K Takeda; T Nakayama; M Taniguchi; H Bashuda; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

4.  The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.

Authors:  T Nishimura; H Kitamura; K Iwakabe; T Yahata; A Ohta; M Sato; K Takeda; K Okumura; L Van Kaer; T Kawano; M Taniguchi; M Nakui; M Sekimoto; T Koda
Journal:  Int Immunol       Date:  2000-07       Impact factor: 4.823

5.  Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression.

Authors:  A B Adams; M M Durham; L Kean; N Shirasugi; J Ha; M A Williams; P A Rees; M C Cheung; S Mittelstaedt; A W Bingaman; D R Archer; T C Pearson; E K Waller; C P Larsen
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

6.  Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions.

Authors:  P A Taylor; C J Lees; H Waldmann; R J Noelle; B R Blazar
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

Review 7.  Role of NK and NKT cells in solid organ transplantation.

Authors:  Johann Pratschke; Diana Stauch; Katja Kotsch
Journal:  Transpl Int       Date:  2009-04-21       Impact factor: 3.782

8.  Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment.

Authors:  T Wekerle; J Kurtz; H Ito; J V Ronquillo; V Dong; G Zhao; J Shaffer; M H Sayegh; M Sykes
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

9.  Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning.

Authors:  M M Durham; A W Bingaman; A B Adams; J Ha; S Y Waitze; T C Pearson; C P Larsen
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

10.  CD1d-dependent activation of NKT cells aggravates atherosclerosis.

Authors:  Emmanuel Tupin; Antonino Nicoletti; Rima Elhage; Mats Rudling; Hans-Gustaf Ljunggren; Göran K Hansson; Gabrielle Paulsson Berne
Journal:  J Exp Med       Date:  2004-01-26       Impact factor: 14.307

View more
  4 in total

Review 1.  Transplantation tolerance through mixed chimerism.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2010-08-31       Impact factor: 28.314

2.  Islet allograft tolerance in the absence of invariant natural killer T cells.

Authors:  Xiufeng Chu; Elizabeth Kilpatrick; Xiang Xiao; Wentao Liu; Gulcin Demirci; Mark Exley; Xian C Li
Journal:  Clin Immunol       Date:  2011-09-23       Impact factor: 3.969

3.  Signal one and two blockade are both critical for non-myeloablative murine HSCT across a major histocompatibility complex barrier.

Authors:  Kia J Langford-Smith; Zara Sandiford; Alex Langford-Smith; Fiona L Wilkinson; Simon A Jones; J Ed Wraith; Robert F Wynn; Brian W Bigger
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

Review 4.  The applications of bone marrow-derived stem cells to induce tolerance and chimerism in organ transplantation.

Authors:  M Ebrahimi; N Aghdami
Journal:  Int J Organ Transplant Med       Date:  2010
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.